https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-06-01 12:00:162025-06-24 17:38:56BB-101 drug received Taiwan FDA approval for clinical trials and began Phase II clinical trials at 3 medical centers in Taiwan.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-03-01 12:00:262025-06-24 17:39:05Submitted application to Taiwan FDA to conduct BB-101 Phase II clinical trial.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-01-01 12:00:552025-06-24 17:38:24Submitted application to the US FDA to conduct BB-101 Phase II clinical trial.
BB-101 drug received Taiwan FDA approval for clinical trials and began Phase II clinical trials at 3 medical centers in Taiwan.
Submitted application to Taiwan FDA to conduct BB-101 Phase II clinical trial.
Submitted application to the US FDA to conduct BB-101 Phase II clinical trial.